Technology Innovation Institute Joins the Quantum Computing Challenge with Launch of Open-Source ‘Qibo’
Technology Innovation Institute (TII), the applied research pillar of Advanced Technology Research Council (ATRC), today announced that its Quantum Research Centre (QRC) has developed the first simulation version of 'Qibo', a versatile open-source quantum computing programming framework, in collaboration with researchers from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210426005389/en/
Professor José Ignacio Latorre, Chief Researcher, Quantum Research Centre (QRC), Technology Innovation Institute (TII) (Photo: AETOSWire)
The development follows a series of rapid announcements at TII since the first ATRC board meeting in August 2020.
TII strives to create innovation for a better world. The development of an open-source programming framework will have compelling benefits for the global research community.
Qibo is designed to support quantum algorithms across different computer systems, including support to hardware accelerators such as graphics processing units (GPUs) and multiple quantum devices. This versatility makes Qibo easy to use for quantum programming and accelerates research and applications. Written in programming languages such as Python and C/C++, Qibo is the entry point for a full stack programming platform, able to run quantum algorithms across different quantum computers and simulators.
Qibo is a joint project by Quantum Research Centre; Qilimanjaro Quantum Tech, the Barcelona-based quantum computing company; and researchers at other global centres. TII’s Quantum Research Centre team is led by Chief Researcher Prof José Ignacio Latorre. The first release of Qibo was published in September 2020, with the final version set for launch within the next two years.
Speaking on the announcement, His Excellency Faisal Al Bannai, Secretary General of Advanced Technology Research Council (ATRC), said: “The fact that Qibo is open-source will be a significant advantage to the world of programming and marks a major contribution to the research community and the advancement of scientific inquiry. Initial benchmark studies that show Qibo outperforming other computing languages is a clear indication of the quality of research currently being undertaken at Quantum Research Centre at Technology Innovation Institute."
Prof José Ignacio Latorre, Chief Researcher at Quantum Research Centre, said: “We are committed to innovation that transcends boundaries. The quantum advantage in computing will offer notable benefits to broader society, ranging from life-sciences, artificial intelligence, and finance.”
QRC is one of seven initial dedicated research centres that are part of TII. The Qibo code published in the research paper can be accessed via a GitHub link [https://qibo.science/].
About Technology Innovation Institute (TII)
Technology Innovation Institute (TII) is the dedicated ‘applied research’ pillar of Advanced Technology Research Council (ATRC). TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation.
For more information, visit www.tii.ae
About Quantum Research Centre (QRC)
Quantum Research Centre – at Technology Innovation Institute (TII) – has been created to develop world-class quantum-theoretical and experimental research by building and operating the first quantum computer in the MENA region while advancing quantum communications and quantum sensors. The Centre aims to develop pioneering technologies backed by the expertise of an international team of leading researchers, dedicated to achieving a ‘Quantum Advantage’ which will transform the power and scope of computers.
For more information, visit https://quantum.tii.ae/
Connect with us on social media:
LinkedIn:
https://www.linkedin.com/company/tiiuae/
Twitter:
https://twitter.com/TIIuae
Instagram:
https://www.instagram.com/tiiuae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005389/en/
Contact information
Technology Innovation Institute
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom